DXR Daxor Corp.

New Research Shows Daxor’s BVA-100® Blood Test Provides Unique Benefit in Detecting Anemia and Heart Failure Risk, Presented at the Heart Failure Society of America Meeting 2020

New Research Shows Daxor’s BVA-100® Blood Test Provides Unique Benefit in Detecting Anemia and Heart Failure Risk, Presented at the Heart Failure Society of America Meeting 2020
EN
06/10/2020

Underlying

DXRDaxor Corp.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Daxor Corp.

 PRESS RELEASE
Free
DXR DAXOR CORP.

Daxor Corporation CEO and President Michael Feldschuh Provides Corpora...

Daxor Corporation CEO and President Michael Feldschuh Provides Corporate Update in Letter to Shareholders Oak Ridge, TN, March 03, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: DXR), the global leader in blood volume measurement technology today issued a corporate update in a Letter to Shareholders filed in its certified shareholder report on Form N-CSR on March 2, 2026 from CEO & President, Michael Feldschuh. Dear Valued Shareholders, "To measure is to know. If you cannot measure it, you cannot improve it." — Lord Kelvin Lord Kelvin’s timeless scientific principle perfectly encapsulates the miss...

March 3, 2026 1 EN
 PRESS RELEASE
Free
DXR DAXOR CORP.

Daxor Corporation Reports 2025 Fiscal Year Results: Operating Revenue ...

Daxor Corporation Reports 2025 Fiscal Year Results: Operating Revenue Up 45%, Net Asset Value Rises to $9.07 Per Share Strategic Realignment to Clinical Growth Supported by FDA 510(k) Clearance for Next-Generation Blood Volume Analyzer Oak Ridge, TN, March 03, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: DXR), the global leader in blood volume measurement technology, today announces financial and operating results for the fiscal year ended December 31, 2025. The company reported a transformative year characterized by significant growth in its operating division and a substantial increase in total ...

March 3, 2026 1 EN
 PRESS RELEASE
Free
DXR DAXOR CORP.

Daxor Scales Outpatient Presence; Launches BVA Diagnostic Program in T...

Daxor Scales Outpatient Presence; Launches BVA Diagnostic Program in Tennessee Expansion Leverages Daxor’s ezBVA Lab to Deliver 98% Accurate Diagnostics with Zero Capital Investment  Oak Ridge, TN, Feb. 24, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: DXR), the global leader in blood volume measurement technology, continues its strategic expansion into the outpatient cardiology market with the opening of a new BVA program at a leading healthcare facility in Southern Middle Tennessee. This integration brings Daxor’s state-of-the-art testing to a high-volume preventative care setting, driving clinic...

February 24, 2026 1 EN
 PRESS RELEASE
Free
DXR DAXOR CORP.

Daxor Corporation Announces Transition To Securities Exchange Act of 1...

Daxor Corporation Announces Transition To Securities Exchange Act of 1934 Reporting Company, Reaffirming Focus on Core Blood Volume Analysis and Diagnostic Business Oak Ridge, TN, Feb. 10, 2026 (GLOBE NEWSWIRE) -- (NASDAQ: DXR), the global leader in blood volume measurement technology, today announced its intention to transition its primary regulatory reporting framework from the Investment Company Act of 1940 (the Investment Company Act) to the Securities Exchange Act of 1934 (the “Exchange Act”), subject to its completion of required regulatory filings and approvals. This transition re...

February 10, 2026 1 EN
 PRESS RELEASE
Free
DXR DAXOR CORP.

Daxor Corporation Announces $9 Million Registered Direct Offering

Daxor Corporation Announces $9 Million Registered Direct Offering OAK RIDGE, TN, Jan. 23, 2026 (GLOBE NEWSWIRE) -- Daxor Corporation (NasdaqCM: DXR) (“Daxor” or the “Company”) announced today that it has entered into a definitive agreement with fundamental investors for the purchase and sale of an aggregate of 765,958 shares of its common stock (the “Shares”) at a purchase price per Share of $11.75. The offering is expected to close on or about January 26, 2026, subject to the satisfaction of customary closing conditions. The gross proceeds from the offering to the Company are expected t...

January 23, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch